Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model
Abstract Neoantigen vaccines hold great promise in cancer immunotherapy, but the comparative efficacy of different vaccine platforms, particularly in the context of tumor burden (TB), remains insufficiently studied. In this research, we evaluated the safety and therapeutic efficacy of synthetic long...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-03-01
|
| Series: | Cancer Immunology, Immunotherapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00262-025-03992-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850208456221392896 |
|---|---|
| author | Cao Minh Nguyen Trung T. Vu Minh Nguyen Nguyen Thao-Suong Tran-Nguyen Chi Thien Huynh Quang Thanh Ha Hoai-Nghia Nguyen Le Son Tran |
| author_facet | Cao Minh Nguyen Trung T. Vu Minh Nguyen Nguyen Thao-Suong Tran-Nguyen Chi Thien Huynh Quang Thanh Ha Hoai-Nghia Nguyen Le Son Tran |
| author_sort | Cao Minh Nguyen |
| collection | DOAJ |
| description | Abstract Neoantigen vaccines hold great promise in cancer immunotherapy, but the comparative efficacy of different vaccine platforms, particularly in the context of tumor burden (TB), remains insufficiently studied. In this research, we evaluated the safety and therapeutic efficacy of synthetic long peptide and mRNA-based vaccines, both designed to target identical neoantigens across different Lewis Lung Carcinoma (LLC) tumor burdens. We employed the LLC syngeneic mouse model, a widely used preclinical model for aggressive and immunosuppressive tumors. Our findings demonstrated that the mRNA-based vaccine significantly outperformed the peptide-based vaccine in preventing tumor growth in mice with low TB. These results underscore the potential of mRNA vaccines as a more effective approach for treating aggressive tumors, contributing valuable insights for the future development of neoantigen-based cancer vaccines. |
| format | Article |
| id | doaj-art-4e1f32ef549342a78dcc2849791d256e |
| institution | OA Journals |
| issn | 1432-0851 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Springer |
| record_format | Article |
| series | Cancer Immunology, Immunotherapy |
| spelling | doaj-art-4e1f32ef549342a78dcc2849791d256e2025-08-20T02:10:14ZengSpringerCancer Immunology, Immunotherapy1432-08512025-03-0174411710.1007/s00262-025-03992-7Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma modelCao Minh Nguyen0Trung T. Vu1Minh Nguyen Nguyen2Thao-Suong Tran-Nguyen3Chi Thien Huynh4Quang Thanh Ha5Hoai-Nghia Nguyen6Le Son Tran7Medical Genetics InstituteMedical Genetics InstituteMedical Genetics InstituteMedical Genetics InstituteBiotechnology Center of Ho Chi Minh CityBiotechnology Center of Ho Chi Minh CityMedical Genetics InstituteMedical Genetics InstituteAbstract Neoantigen vaccines hold great promise in cancer immunotherapy, but the comparative efficacy of different vaccine platforms, particularly in the context of tumor burden (TB), remains insufficiently studied. In this research, we evaluated the safety and therapeutic efficacy of synthetic long peptide and mRNA-based vaccines, both designed to target identical neoantigens across different Lewis Lung Carcinoma (LLC) tumor burdens. We employed the LLC syngeneic mouse model, a widely used preclinical model for aggressive and immunosuppressive tumors. Our findings demonstrated that the mRNA-based vaccine significantly outperformed the peptide-based vaccine in preventing tumor growth in mice with low TB. These results underscore the potential of mRNA vaccines as a more effective approach for treating aggressive tumors, contributing valuable insights for the future development of neoantigen-based cancer vaccines.https://doi.org/10.1007/s00262-025-03992-7Lewis lung carcinomaNeoantigenSynthetic long peptide vaccinemRNA-based vaccinemRNA-LNPsCancer immunotherapy |
| spellingShingle | Cao Minh Nguyen Trung T. Vu Minh Nguyen Nguyen Thao-Suong Tran-Nguyen Chi Thien Huynh Quang Thanh Ha Hoai-Nghia Nguyen Le Son Tran Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model Cancer Immunology, Immunotherapy Lewis lung carcinoma Neoantigen Synthetic long peptide vaccine mRNA-based vaccine mRNA-LNPs Cancer immunotherapy |
| title | Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model |
| title_full | Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model |
| title_fullStr | Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model |
| title_full_unstemmed | Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model |
| title_short | Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model |
| title_sort | neoantigen based mrna vaccine exhibits superior anti tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model |
| topic | Lewis lung carcinoma Neoantigen Synthetic long peptide vaccine mRNA-based vaccine mRNA-LNPs Cancer immunotherapy |
| url | https://doi.org/10.1007/s00262-025-03992-7 |
| work_keys_str_mv | AT caominhnguyen neoantigenbasedmrnavaccineexhibitssuperiorantitumoractivitycomparedtosyntheticlongpeptidesinaninvivolungcarcinomamodel AT trungtvu neoantigenbasedmrnavaccineexhibitssuperiorantitumoractivitycomparedtosyntheticlongpeptidesinaninvivolungcarcinomamodel AT minhnguyennguyen neoantigenbasedmrnavaccineexhibitssuperiorantitumoractivitycomparedtosyntheticlongpeptidesinaninvivolungcarcinomamodel AT thaosuongtrannguyen neoantigenbasedmrnavaccineexhibitssuperiorantitumoractivitycomparedtosyntheticlongpeptidesinaninvivolungcarcinomamodel AT chithienhuynh neoantigenbasedmrnavaccineexhibitssuperiorantitumoractivitycomparedtosyntheticlongpeptidesinaninvivolungcarcinomamodel AT quangthanhha neoantigenbasedmrnavaccineexhibitssuperiorantitumoractivitycomparedtosyntheticlongpeptidesinaninvivolungcarcinomamodel AT hoainghianguyen neoantigenbasedmrnavaccineexhibitssuperiorantitumoractivitycomparedtosyntheticlongpeptidesinaninvivolungcarcinomamodel AT lesontran neoantigenbasedmrnavaccineexhibitssuperiorantitumoractivitycomparedtosyntheticlongpeptidesinaninvivolungcarcinomamodel |